[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Kissei Pharmaceutical Co., Ltd.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":105},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,40,62,85],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":39},"100639605","phase-2-a-clinical-trial-of-olutasidenib-in-patients-with-acute-myeloid-leukemia-100639605",false,"NCT07604064","A Clinical Trial of Olutasidenib in Patients With Acute Myeloid Leukemia","A Phase II Clinical Trial of Olutasidenib in Patients With Relapsed or Refractory IDH1 Mutation-Positive Acute Myeloid Leukemia","Inclusion Criteria:\n\n* Japanese patients who personally provide written informed consent to participate in this clinical trial\n* Patients with a confirmed diagnosis of AML based on WHO classification (2022 edition) (except acute promyelocytic leukemia with t (15:17) translocation)\n* Patients with relapsed or refractory AML who may or may not have undergone allogeneic hematopoietic stem cell transplantation.\n* Patients with IDH1 gene mutation confirmed by central confirmation after relapse or refractoriness\n\nExclusion Criteria:\n\n* Patients with IDH2 mutations or patients with a history of IDH2 inhibitor treatment\n* Patients who are intolerant to IDH1 inhibitors\n* Patients who are deemed inappropriate for the clinical trial by the investigator or sub-investigator","ALL","18 Years",{"count":19,"type":20},3,"ESTIMATED","INTERVENTIONAL",[23],"PHASE2","This clinical trial is a multicenter, single-arm, open-label study to evaluate the safety, efficacy, pharmacokinetics, and pharmacodynamics of olutasidenib administered orally twice daily under fasting conditions for one cycle of 28 days in at least 3 Japanese patients with relapsed or refractory IDH1 mutation-positive AML.",[26],"Relapsed or Refractory IDH1 Mutation-Positive Acute Myeloid Leukemia","RECRUITING","2026-05-22",{"date":30,"type":31},"2026-05-27","ACTUAL",{"date":33,"type":20},"2026-06",{"date":35,"type":20},"2030-09",{"name":37,"class":38},"Kissei Pharmaceutical Co., Ltd.","INDUSTRY",1,{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":4,"eligibilityCriteria":46,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":47,"targetDuration":4,"studyType":21,"phases":49,"briefSummary":51,"conditions":52,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":54,"lastUpdatePostDateStruct":55,"startDateStruct":57,"completionDateStruct":59,"leadSponsor":61,"locationsCount":39},"100596029","phase-3-confirmatory-study-3-of-kps-0373-in-patients-with-spinocerebellar-degeneration-100596029","NCT07040137","Confirmatory Study 3 of KPS-0373 in Patients With Spinocerebellar Degeneration","Phase III Confirmatory Study 3 of KPS-0373 in Patients With Spinocerebellar Degeneration","Inclusion Criteria:\n\n* Japanese SCD patients with mild to moderate ataxia\n\nExclusion Criteria:\n\n* Patients with secondary ataxia\n* Patients with clinically significant hepatic, renal, or cardiovascular dysfunction",{"count":48,"type":20},142,[50],"PHASE3","This is a multicenter, randomized, double-blind, placebo-controlled, parallel-group, phase III study to evaluate the efficacy and safety of KPS-0373 given once daily after breakfast in 142 patients with spinocerebellar degeneration . This study consists of the 4-week screening period, 24-week treatment period, and 4-week follow-up period.",[53],"Spinocerebellar Degeneration","2025-06-25",{"date":56,"type":31},"2025-06-27",{"date":58,"type":20},"2025-07",{"date":60,"type":20},"2027-03-31",{"name":37,"class":38},{"id":63,"slug":64,"hasResults":11,"nctId":65,"briefTitle":66,"officialTitle":67,"acronym":4,"eligibilityCriteria":68,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":69,"targetDuration":71,"studyType":72,"phases":4,"briefSummary":73,"conditions":74,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":80,"completionDateStruct":82,"leadSponsor":84,"locationsCount":39},"100574360","special-drug-use-results-survey-for-long-term-useavacopan-100574360","NCT06758271","Special Drug Use-results Survey for Long-term Use（Avacopan）","Special Drug Use-results Survey for Long-term Use","Inclusion Criteria:\n\n* Patients with granulomatosis with polyangiitis or microscopic polyangiitis who are treatment with avacopan",{"count":70,"type":20},250,"2 Years","OBSERVATIONAL","The purpose of this survey is evaluating the safety and efficacy of long-term administration of avacopan for Japanese patients with microscopic polyangiitis or granulomatosis with polyangiitis under actual conditions of use.",[75,76],"Microscopic Polyangiitis (MPA)","Granulomatosis With Polyangiitis (GPA)","2025-01-15",{"date":79,"type":31},"2025-01-17",{"date":81,"type":31},"2022-07-29",{"date":83,"type":20},"2028-05-31",{"name":37,"class":38},{"id":86,"slug":87,"hasResults":11,"nctId":88,"briefTitle":89,"officialTitle":89,"acronym":4,"eligibilityCriteria":90,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":91,"targetDuration":93,"studyType":72,"phases":4,"briefSummary":94,"conditions":95,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":39},"100574282","special-drug-use-results-survey-for-long-term-use-fostamatinib-100574282","NCT06757257","Special Drug Use-results Survey for Long-term Use (Fostamatinib)","Inclusion Criteria:\n\n* Patients with chronic idiopathic thrombocytopenic purpura who are treatment with fostamatinib for the first time.",{"count":92,"type":20},149,"18 Months","The purpose of this survey is evaluating the safety and efficacy of long-term administration of fostamatinib for Japanese patients with chronic idiopathic thrombocytopenic purpura under actual conditions of use.",[96],"Chronic Idiopathic Thrombocytopenic Purpura","2024-12-26",{"date":99,"type":31},"2025-01-03",{"date":101,"type":31},"2023-05-29",{"date":103,"type":20},"2028-09-30",{"name":37,"class":38},""]